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ABSTRACT 
 
Aim: Patients with rheumatoid arthritis (RA) and co-existent Bronchiectasis (BRRA) 
have a 5-fold increased mortality compared to rheumatoid arthritis alone. Yet 
previous studies have found no difference in clinical and serological markers of RA 
disease severity between BRRA patients and RA alone. RA disease activity 
measures such as DAS28-CRP and anti-cyclic citrullinated peptide antibodies (anti-
CCP) however have not been studied, so we assessed these parameters in patients 
with BRRA and RA alone.  
Methods: BRRA patients (n = 53) had HRCT proven bronchiectasis without any 
interstitial lung disease and ≥2 respiratory infections/year. RA alone patients (n = 50) 
had no clinical or radiological evidence of lung disease. DAS28-CRP, rheumatoid 
factor (IgM) and anti-CCP were measured in all patients, together with detailed 
clinical and radiology records.  
Results: In BRRA, BR predated RA in 58% of patients. BRRA patients had higher 
DAS28 scores (3.51 vs. 2.59), higher levels of anti-CCP (89 vs. 46%) and RF (79 vs. 
52%) (p = 0.003) compared to RA alone. Where hand and foot radiology findings 
were recorded, 29/37 BRRA (78%) and 13/30 (43%) RA alone had evidence of 
erosive change (p = 0.003). There were no significant differences between groups in 
smoking history or DMARD/biologic therapy.  
Conclusions: Increased levels of RA disease activity, severity and RA 
autoantibodies are demonstrated in patients with RA and co-existent bronchiectasis 
compared to patients with RA alone, despite lower tobacco exposure. This study 
demonstrates that BRRA is a more severe systemic disease than RA alone. 
 
 
 
 
  
Page 2 of 21
International Journal of Rheumatic Diseases
International Journal of Rheumatic Diseases
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review Only
3 
 
 
INTRODUCTION 
The association between Rheumatoid arthritis (RA) and bronchiectasis (BR) has 
been recognized for many years. Indeed, in 1967 Walker observed an ten-fold 
increased prevalence of bronchiectasis in an RA population when compared to a 
population of patients with degenerative joint disease 1. Modern studies have found 
symptomatic bronchiectasis with a prevalence of 2.7% in RA subjects, compared to 
0.03% in the general population 2. High resolution computed tomography (HRCT) 
studies demonstrate the prevalence to be much higher, with radiological BR in RA 
populations repeatedly reported in the region of 30% 3-6. 
Studies have addressed the characteristics of RA patients with bronchiectasis 
with no consensus in terms of presence or absence of a positive rheumatoid factor, 
rheumatoid nodules, joint damage and functional impairment 5, 7, 8. Infectious 
complications in patients with RA and bronchiectasis are common and have serious 
implications for management with disease modifying anti rheumatic drug (DMARD) 
and biologic therapy 9. Despite this, two small contrasting studies have evaluated 
DMARD and biologic therapies in patients with RA and co-existent BR. One study 
demonstrated lower infective exacerbations of BR in patients on DMARDs 10, while 
the other found more infective exacerbations in patients on biologics 11. The co-
existence of these conditions has significant health implications, indeed patients with 
RA and BR have been shown to have mortality rates 7.3 times that of the general 
population, 5 times that of patients with RA alone and 2.4 times that of patients with 
BR alone 12. 
 
The temporal relationship and significance of the association between BR and 
RA has been a subject of great interest for many years. Numerous studies have 
found that BR precedes RA often by 20-30 years 1, 8, 13, 14, supporting the hypothesis 
that BR may be involved in the pathogenesis of RA 1, 8, 13, 14. In contrast, other 
studies have demonstrated RA precedes BR and argue that BR is an extra-articular 
manifestation of severe late RA 9, 15. Importantly, recent HRCT studies demonstrate 
an increased prevalence of subclinical airway abnormalities consistent with BR at 
first diagnosis in RA patients 16, 17 supporting the hypothesis that BR typically 
precedes RA and that BR could play a role in the pathogenesis of RA.  
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Previous studies of BR and coexistent RA are limited in terms of disease definition, 
indeed the majority pre-date HRCT and modern tests for RA autoantibodies, 
particularly anti-CCP antibodies. Previous studies of patients with HRCT proven BR 
and co-existent RA have been limited by low numbers, with typically less than 25 
cases reported 8, 13, 18, 19. Initially no link between anti-CCP and lung disease was 
found 20, but two studies have reported an association between anti-CCP and 
airways disease 21 and interstitial lung disease 22 in patients with established RA. 
Recently, Demoruelle and co-workers 16 have identified an association between anti-
CCP positive subjects without inflammatory arthritis and the presence of airway 
abnormalities on HRCT. This evidence supports the hypothesis that the lung may be 
an initiating site for the development of RA.  
This cross-sectional obs rvational study details the natural history, disease severity 
and RA autoantibody positivity in the largest study of well-defined HRCT proven non-
cystic fibrosis BR and co-existent RA subjects reported to date 17-19, 23.  We have 
compared the results with those obtained from a control group of RA patients with no 
evidence of lung disease.  
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SUBJECTS AND METHODS 
Subjects were chiefly identified by review of RA and BR patient databases searching 
for those with documented co-existent disease in respective specialist clinics at four 
different hospitals across the UK. These comprised Freeman Hospital, Newcastle 
upon Tyne; Queen Elizabeth Hospital, Gateshead; Royal Cornwall Hospital, Truro 
and North Bristol NHS Trust Hospital. Rheumatology and respiratory consultants at 
participating hospitals were contacted directly and invited to participate by confirming 
their willingness to allow access to their patients with twin diagnoses of RA and BR, 
together with access to their medical records. To address any potential sources of 
recruitment bias, site of recruitment and method of identification was recorded for 
each participant allowing study outcome measures to be compared between these 
sub-groups. Ethical approval was obtained at all centres participating in this study 
(multi centre ethics – IRAS 12324) and conforms to the provisions of the Declaration 
of Helsinki in 1995. All recruitment was completed between May 2012 and May 
2013. 
We identified adult patients (>18 years) with HRCT proven symptomatic non-cystic 
fibrosis BR reported by an independent radiologist and a history of ≥2 respiratory 
infections per year determined by a clinician who met the 2010 American College of 
Rheumatology (ACR) and European League Against Rheumatism (EULAR) criteria 
for RA 17-19, 23. Patients with any other form of lung disease in addition to BR were 
specifically excluded from the study. This included all those with established 
interstitial lung disease, asthma or advanced emphysema. All participating centres 
employed these criteria. In this current study we did not assess the severity of 
bronchiectasis by HRCT, but we would consider doing so in future more detailed 
studies. All BRRA patients were under specialist respiratory follow-up, their annual 
pulmonary function tests and the number of lower respiratory infections requiring 
antibiotics in the past 12 months were recorded as part of the study. 
In addition to patients with BR and co-existent RA we recruited 50 control RA 
patients. These patients met the ACR/EULAR criteria 24 for RA but had no clinical or 
radiological evidence of any lung disease. They were consecutively identified from 
the same hospital sites, using the same mechanisms over the same time period. 
Moreover, All RA control patients were reviewed by a physician and had a normal clinical 
examination, with no evidence of respiratory symptoms. Chest x-ray and lung function 
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results were also reviewed for all RA patients and when they were performed, were within 
normal limits.  
Data collection 
We recorded demographic details, together with the date of onset of symptoms and 
date of diagnosis for RA and BR by face-to-face assessment undertaken by one of 
us (EP). Current RA therapy and a detailed smoking history were also recorded. RA 
disease activity and severity measures were recorded for both groups including the 
disease activity score in 28 joints (DAS-28) performed by a single Rheumatologist 
(EP), C-reactive protein (CRP) levels, radiological evidence of erosive disease and 
RA autoantibody status. RA Remission was defined by a DAS28-CRP score <2.6 25.  
Anti-CCP was measured in serum by ELISA assay using the Phadia Elia TM CCP (2nd 
generation). We classified levels of <7 U/ml as negative, levels of 7-10 U/ml as 
equivocal and levels >10 U/ml as positive. In accordance with ACR classification, 
positive results were subdivided with results greater than 30 U/ml (three-fold the 
laboratory upper limit of normal) considered high positive. Levels above 340 U/ml 
(the upper detection limit) were considered very high positive. Measurement of 
rheumatoid factor (RF) in participant serum was performed using ROCHE 
Diagnostics Hitachi Modular P. We classified levels <14 U/ml as negative and levels 
>14 U/ml as positive. Once more, positive results were subdivided using a definition 
of >3 times the upper limit of normal to define highly positive and measures above 
the upper detection limit >130 U/ml to define very highly positive. 
Receiver operating characteristics (ROC) curves were generated comparing test 
results for RF and anti-CCP between RA patients versus BRRA patients, using 
Prism 5 software and the area under each ROC curve calculated, together with 95% 
confidence intervals. 
Statistical analysis 
Continuous variables are expressed as median +/- interquartile range (IQR). Fisher’s 
exact test, the Mann Whitney U test and multivariate analysis were used to compare 
categorical variables and outcome measurements between the two groups of 
patients with RA and BR and the Kruskal-Wallis test to compare variables between 
greater than two groups. Comparisons of diagnostic specificity and sensitivity were 
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made together with positive predictive values (PPV) and negative predictive values 
(NPV) for patients in both cohorts, positive for either RF, anti-CCP or both. All 
statistical tests were two sided and P values <0.05 were considered statistically 
significant. 
RESULTS 
BR and RA Natural History: We identified 53 patients with non-cystic fibrosis BR and 
coexistent RA (BRRA). Among these, in 31 cases (58%) symptoms of BR preceded 
the onset of RA by a median (IQR) of 25 (19) years. In another 21 (40%), RA 
symptoms preceded BR by a median (IQR) of 18 (14) years. In the remaining 
individual, BR and RA symptoms developed simultaneously. The delay between 
symptom onset and diagnosis differed significantly for the two conditions. While 43 
(81%) reported that the onset of RA symptoms occurred within 12 months of the 
diagnosis of RA, only 21 (40%) reported that the diagnosis of BR was made within a 
year of the onset of respiratory symptoms (p<000.1). Indeed, the median duration of 
delay between BR symptom onset and diagnosis for the 53 cases identified was 
11.87 years in comparison to 2 years for RA. All BRRA patients had HRCT evidence 
of Bronchiectasis without any other lung disease. Although fibrotic lung disease is a 
recognised complication of disease modifying therapy serial HRCT scans were 
beyond the scope of this study. It is therefore impossible to exclude new drug 
induced pathology, however all BRRA patients were under specialist respiratory 
follow-up and were excluded from the study if evidence of fibrotic lung disease was 
found on HRCT or in their clinical history. 
Demographics: In addition to the 53 BRRA patients we recruited 50 RA controls 
without lung disease. The gender and age distribution was similar between the two 
groups, however patients with BRRA were found to have a longer duration of RA 
(Table 1). To control for this we frequency matched 38 RA patients as case controls 
for 38 BRRA patients by RA disease duration (Table 2). 
RA Disease Severity and Activity: Comparison of BRRA and RA alone patients 
demonstrate a clearly statistically significant increase in DAS28-CRP in BRRA 
patients of almost 1.0 unit, p=0.003 (Table 1). These differences remained when the 
groups were matched for RA disease duration (Table 2). In addition all components 
of the DAS28-CRP disease activity score except VAS (global) were significantly 
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higher in the BRRA group compared to the RA group matched for RA duration 
(Figure 1).  
Where hand and foot radiology findings were recorded a significantly higher 
percentage of BRRA patients had evidence of erosive disease, once more this 
increase remained when the groups were matched for RA disease duration (Table 1, 
2). Remission rates defined by a DAS28-CRP <2.6 25 were considerably lower for 
the complete BRRA group compared to the RA group [9% versus 28% (p = 0.0001)] 
and for the BRRA group matched for RA disease duration [6% vs 19% (p = 0.002)] 
(Table 1, 2). 
Smoking History: There was no significant difference in the proportion of ex/current 
smokers for the complete BRRA group compared to the RA group [22% versus 28% 
(p = 0.1)] or the BRRA group matched for disease duration [16% versus 18% (p = 
0.8)]. Low mean number of pack years in the ex-smokers was observed in both 
groups (Table 1, 2). Therefore there was no need for statistical adjustment based on 
smoking as a confounder. 
Serology: In total 47 (89%) of the BRRA patients were anti-CCP positive, compared 
to 46% for RA alone (Table 3). The sensitivity (89% versus 79%) and NPV (82% 
versus 69%) for RABR was higher for anti-CCP than RF. This is in agreement with 
previous studies. Notably the proportion of BRRA patients with very highly positive 
anti-CCP results was far greater than the RA group [49% versus 18% (p = 0.001)] 
(Figure 2B). Similarly, the proportion of BRRA patients with very high positive titres 
for RF was significantly statistically different from those with RA alone [32% versus 
14% (p = 0.037)] (Figure 2A). There was a high level of concordance between RF 
and anti-CCP. Indeed, of the anti-CCP positive BRRA patients, 42 (89%) were also 
positive for RF. For the RA group 23 (46%) were anti-CCP positive, the level of 
concordance with RF was similar to the BRRA group with 21 (91%) also positive for 
RF. The combination of measuring RF and anti-CCP antibodies gave a moderate 
increase in the specificity of 58% compared with measuring only RF (48%) or anti-
CCP (54%) alone. The presence of bronchiectasis constituted a greater risk factor 
for developing both anti-CCP and RF antibodies. The values for specificity, 
sensitivity and both positive and negative predictive values are shown in Table 3. 
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ROC analysis provided further evidence that both the RF and anti-CCP assays 
discriminates between BRRA and RA group of patients.  The area under the curve 
for anti-CCP was 0.7302 (P < 0.0001; 95% CI 0.63 – 0.83) and for RF 0.7087 (P < 
0.0003; 95% CI 0.61 – 0.81) (Fig 2 C and D). This indicated that patients with BBRA 
had higher test results for anti-CCP and RF than RA patients, 73% and 71% 
occasions respectively; suggesting anti-CCP has a higher diagnostic performance 
than RF for distinguishing between BRRA and RA alone. If no difference between 
the two groups existed, a value of 0.5 would have been expected. The ROC curve 
for anti-CCP passed closer to upper left hand corner than the RF ROC curve 
indicating that the sensitivity compared at the same specificity value, was higher for 
anti-CCP antibody titres than RF antibodies (Figure 2C & D). 
RA Therapeutics: There was no significant difference in the proportion of patients on 
no DMARD or biologic therapy, DMARD monotherapy, DMARD combination therapy 
or biologic therapy between the complete BRRA group and the RA group or the 
BRRA group and the RA group matched for disease duration (Table 1, 2) and were 
not considered confounders warranting statistical adjustment. However both the 
complete BRRA group (10/53) and the matched BRRA group (7/38) had a 
significantly higher proportion of patients on oral prednisolone compared to both the 
unmatched RA groups (1/50) and matched RA groups (1/38) (Table 1, 2). In 
previous studies intra-articular steroid injection in RA patients can result in 
diminished ESR and CRP levels 26. However in our study CRP levels in BBRA 
versus RA patients was consistently higher, despite a higher number of BBRA 
patients being treated with oral prednisolone compared to RA patients.  
Effect of different Recruitments sites/methods: There were no significant differences 
in mean values of DAS28-CRP in those RA patients with BR identified by local 
clinicians as opposed to those identified by database [mean 3.65 versus 3.38 
(p=0.28)]. Furthermore, there was no difference between DAS28-CRP scores 
between the 4 recruitment hospital sites [median Bristol 2.88 versus Freeman 3.45 
versus Gateshead 3.1 vs Cornwall 3.7 (p = 0.12 Kruskal-Wallis test)]. 
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DISCUSSION 
All measures of disease activity and severity were found to be significantly higher in 
the BRRA group compared to the RA alone group. This difference remained when 
the groups were matched for RA disease duration. Despite these findings 
DMARD/biologic treatment was no more aggressive in the BRRA group suggesting 
under treatment of RA in this patient group. It is likely this reflects common clinical 
concerns that DMARD/biologic treatment may exacerbate respiratory infections 9, 11. 
The challenge faced by clinicians is highlighted by the significant increase in 
prednisolone use in the BRRA group. Prednisolone is often prescribed when there 
are concerns over infection risk despite itself being well recognised to increase the 
risk of infections 27, 28. Indeed, there is currently no consensus on DMARD/biologic 
therapies in patients with RA and co-existent BR and further studies are urgently 
required, especially given the prevalence rates of up to 30% 3-6.  
While we have analysed the sensitivity and specificity of anti-CCP and RF to 
determine the co-existence of BRRA, It would be misleading to give a specific cut-off 
value for the level of anti-CCP or RF to predict the co-existence of BR and RA from 
this study.  Indeed, it is important to recognise that given RA autoantibody positivity 
was lower in our RA alone group than would be expected in the general RA 
population, if this low level is a chance result it would result in a gross over-estimate 
of the sensitivity of anti-CCP and RF to determine the presence of BR. To determine 
a cut off value with any certainty larger numbers would be required, including 
patients with RA alone with HRCT evidence confirming the absence of lung disease. 
This was not possible within the restrictions of our ethics.  
Based on ROC curve analysis, we demonstrated that the presence of anti-CCP 
antibodies and RF in BRRA patients had a better diagnostic performance than in RA 
alone. RA autoantibodies levels, especially anti-CCP, were very strongly positive in 
the BRRA group significantly more so than among RA controls. However, tobacco 
consumption (a well-recognised environmental risk factor for anti-CCP positive RA 
29) was low, suggesting that other factors must drive the very high levels of anti-CCP 
positivity. The very high levels of anti-CCP antibodies in our BRRA group, in addition 
to recent findings of high levels of antibodies to citrullinated peptides in bronchiolar 
lavage fluid 30, subclinical HRCT lung abnormalities at diagnosis of RA 17 and 
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increased prevalence of lung abnormalities in RA-autoantibody positive subject 
without RA 16 all support the hypothesis that lung pathology may play a role in the 
development of anti-citrulline immunity in the pathogenesis of RA 30, 31. In our 
previous study, we found that bronchiectasis patients with no evidence of RA had 
higher RF positivity compared to age-sex matched controls. A small but significant 
proportion of these were also anti-CCP positive and over a 12 month period 
developed RA 32 .  
RA-autoantibody level positivity and the proportion of patients on biologic therapy 
were lower than anticipated in our RA alone group for UK clinical practice despite 
identical recruitment methods. This may reflect our exclusion of RA patients with any 
clinical or radiological evidence of lung disease. This is the correct control group in 
the context of this study. Indeed, if the hypothesis that lung pathology plays a role in 
the development of anti-citrulline immunity in RA is correct, we would expect to see 
lower RA autoantibodies, lower disease activity and lower RA severity in a selected 
group of RA patients without evidence of lung disease compare to an unselected RA 
patient group.   
Limitations of our study include the possibility of unrecognised case selection bias. In 
addition, we did not introduce any formal mechanism for double-checking the results 
of CT scanning reports. 
In summary we have demonstrated high levels of RA disease activity, severity and 
RA autoantibodies in a group of patients with RA and co-existent bronchiectasis in 
spite of little tobacco exposure. Further research involving patients with RA and co-
existent bronchiectasis is required on a pathogenesis level to investigate the 
potential role for lung pathology in the development of citrulline immunity in RA and 
on a clinical level to help guide physicians in selecting appropriate therapeutic 
options for this challenging patient group. 
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Figure legends  
Figure 1: Individual (A) joint scores and (B) CRP/VAS components of DAS28-CRP 
for patients with RA alone (RA) with RA co-existent bronchiectasis (BRRA). Groups 
matched for RA disease duration (BRRA n=38, RA n=38). Differences between 
groups was assessed using the Mann-Whitney Test; * p<0.05; ** P<0.01; ns – not 
significant  
 
Figure 2: Comparative frequency and degree of seropositivity for (A) RF and (B) 
anti-CCP in BRRA (n=53) and RA (n=50) alone. ROC curves for the measurement of 
(C) rheumatoid factor and (D) anti-CCP in BBRA vs. RA patients. Area under the 
curves for RF is 0.7087, for anti-CCP 0.7302 
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Table 1:  Characteristics of patients with RA with and without co-existent 
Bronchiectasis 
Demographics BRRA 
(n=53) 
RA Alone 
(n=50) 
p value 
Female, number (%) 38 (72) 36 (72) 1.000 
Age in years, median (IQR) 69 (12) 66 (15) 0.069 
Duration RA in years, median (IQR) 19 (24) 12 (14) 0.001* 
Smoking History 
Ex/Current Smoker, number (%) 22 (42) 28 (56) 0.101 
Pack Years, median (IQR) 0 (12) 3 (20) 0.232 
Disease Activity/Severity 
DAS28-CRP, median (IQR) 3.51 (1.16) 2.59 (1.76) 0.003* 
Erosive Disease on X-ray, number (%)i 29 (78) 13 (43) 0.003* 
RA in remission, number (%)ii 9 (17) 28 (53) <0.0001* 
RA Autoantibody Positivity 
ACPA positivity, number (%) 47 (89) 23 (46) <0.0001* 
RF positivity, number (%) 42 (79) 26 (52) 0.003* 
RA Therapeutics 
No current DMARD/Biologic therapy, number 
(%) 
7 (13) 3 (6) 0.32 
DMARD monotherapy, number (%) 25 (47) 27 (51) 0.56 
DMARD combination, number (%) 12 (23) 17 (34) 0.27 
Biologic, number (%)  9 (17) 3 (6) 0.13 
Oral prednisolone, number (%)iii 10 (19) 1 (2) 0.0082* 
i. Limited x-ray data available, n= 37 BRRA and n=30 RA alone. 
ii. RA Remission defined by a DAS28-CRP score <2.6 26  
iii. Oral prednisolone either alone or in combination with DMARDs/Biologics 
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Table 2:  Characteristics of patients with RA with and without co-existent 
Bronchiectasis matched for RA disease duration 
Demographics BRRA 
(n=38) 
RA Alone 
(n=38) 
p value 
Female, number (%) 27 (71) 27 (71) 1.000 
Age in years, median (IQR) 70 (12) 66 (13) 0.100 
Duration RA in years, median (IQR) 13 (13) 12 (12) 0.871 
Smoking History 
Ex/Current Smoker, number (%) 16 (42) 18 (47) 0.818 
Pack Years, median (IQR) 0 (17) 0 (19) 0.841 
Disease Activity/Severity 
DAS28-CRP, median (IQR) 3.45 (1.13) 2.59 (1.84) 0.006* 
Erosive Disease on X-ray, number (%)i 20 (74) 8 (36) 0.009* 
RA in remission, number (%)ii 6 (16) 19 (50) 0.002* 
RA Autoantibody Positivity 
ACPA positivity, number (%) 32 (84) 17 (45) 0.001* 
RF positivity, number (%) 28 (74) 19 (50) 0.058 
RA Therapeutics 
No current DMARD/Biologic therapy, number 
(%) 
5 (13) 2 (5) 0.430 
DMARD monotherapy, number (%) 17 (45) 19 (50) 0.819 
DMARD combination, number (%) 8 (21) 14 (37) 0.206 
Biologic, number (%) 8 (21) 3 (8) 0.191 
Oral prednisoloneiii 7 (18) 1 (3) 0.029* 
i. Limited x-ray data available, n= 27 BRRA and n= 22 RA alone. 
ii. RA Remission defined by a DAS28-CRP score <2.6 26 
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Table 3: Diagnostic performance of rheumatoid factor (RF) and anti-CCP in patients 
with RA with and without co-existing lung disease (LD) 
 
Serology RA RA+LD Sensitivity 
(%) 
Specificity 
(%) 
PPV 
(%) 
NPV 
(%) 
RF+ve* 68/103 
(66%) 
42/53 
(79%) 
79 (0.66-
0.89) 
48 (0.34-
0.63) 
62 69 
RF+ve* 8 48/64 
(75%) 
24/32 
(75%) 
75 (0.57-
0.89) 
25 (0.11-
0.43) 
50 50 
RF+ve* 
24 
49/63 
(78%) 
16/21 
(76%) 
76 (0.53-
0.92) 
21 (0.10-
0.37) 
33 64 
RF+ve** 
22 
182/252 
(72%) 
48/59 
(81%) 
81 (0.69-
0.90) 
31 (0.24-
0.38) 
26 84 
Anti-
CCP+ve* 
70/103 
(68%) 
47/53 
(89%) 
89 (0.77-
0.96) 
54 (0.39-
0.68) 
67 82 
 
Anti-CCP 
+ve** 22 
 
223/252 
(88%) 
 
57/59 
(97%) 
 
97 (0.88-
0.99) 
 
14 (0.09-
0.20) 
 
26 
 
93 
RF & 
anti-
CCP+ve* 
63/103 42/53 79 (0.66-
0.89) 
58 (0.43 -
0.72) 
67 73 
* RA vs. RA and coexisting bronchiectasis; **RA vs. RA and coexisting lung disease. 
Bold depicts data from current study.  
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